CLINICAL TRIAL 19117
The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival).
Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.
CLINICAL TRIAL 19337
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Intervention: DC1 Vaccine; Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab; Taxotere (docetaxel); Trastuzumab; carboplatin; docetaxel; rhuMAb HER2 (Trastuzumab)
CLINICAL TRIAL 19650
The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines.
There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence.
This study will use a Dendritic Cell Type 1 (DC1) vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine. Dendritic cells are immune cells that can tell the participant’s immune system to fight infection. This study vaccine will be made from the participant’s blood cells collected from a procedure called leukapheresis.
Status: Currently Open (Subject to Funding)
If you believe you are eligible for one of these trials or studies, please contact Jesse Hevia at Moffitt Cancer Center to arrange an appointment with Dr. Brian Czerniecki, MD, PhD
813-745-5151 or email at firstname.lastname@example.org